Cargando…

The use of hypomethylating agents in hematologic malignancies: treatment preferences and results

AIM: The objective of this article was to compare the efficiency of azacitidine (AZA) and decitabine (DAC) in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) who are not suitable for high-dose chemotherapy. MATERIALS AND METHODS: MDS and AML patients who were treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serin, Istemi, Dogu, Mehmet Hilmi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922247/ https://www.ncbi.nlm.nih.gov/pubmed/35295753 http://dx.doi.org/10.2217/ijh-2020-0019

Ejemplares similares

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)

Recurrence of lymphoma with isolated pericardial mass: a case report
por: Serin, Istemi, et al.
Publicado: (2020)

COVID-19 Pneumonia or Hypereosinophilic Syndrome?
por: Serin, Istemi, et al.
Publicado: (2020)

Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2023)

PB1897: GILTERITINIB IN TURKEY: EARLY ACCESS PROGRAM RESULTS
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2023)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

P570: VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission
por: Sevindik, Omur Gokmen, et al.
Publicado: (2022)

Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia
por: Delmas, Audrey, et al.
Publicado: (2023)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

Radiotheranostic Agents in Hematological Malignancies
por: Caers, Jo, et al.
Publicado: (2022)

Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis
por: Gao, Chong, et al.
Publicado: (2018)

PB2702: POLYPHARMACY IN HEMATOLOGY PRACTISE: A SINGLE CENTER EXPERIENCE
por: Karişmaz, Kadir, et al.
Publicado: (2023)

PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
por: Saavedra, Minerva Montalvo, et al.
Publicado: (2023)

A new parameter in COVID-19 pandemic: initial lactate dehydrogenase (LDH)/Lymphocyte ratio for diagnosis and mortality
por: Serin, Istemi, et al.
Publicado: (2020)

Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome
por: Grimm, Juliane, et al.
Publicado: (2022)

Are Antimotility Agents Safe for Use in Clostridioides difficile Infections? Results From an Observational Study in Malignant Hematology Patients
por: Kuon, Carla, et al.
Publicado: (2020)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

Dramatic response in the dependency to transfusion after low doses of lenalidomide treatment in a 5q-syndrome patient: a case report
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015)

Clinical trials with anti-angiogenic agents in hematological malignancies
por: Medinger, Michael, et al.
Publicado: (2010)

Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?
por: Brinkmann, K, et al.
Publicado: (2014)

Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma
por: Provez, Lien, et al.
Publicado: (2023)

Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents
por: Malkaram, Sridhar A, et al.
Publicado: (2022)

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter
por: Kordella, Chryssoula, et al.
Publicado: (2021)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?
por: Liapis, Konstantinos, et al.
Publicado: (2021)

A Free Radical Scavenger Ameliorates Teratogenic Activity of a DNA Hypomethylating Hematological Therapeutic
por: Sobočan, Nikola, et al.
Publicado: (2019)

The treatment of hematologic malignancies in pregnancy
por: Vandenbriele, C., et al.
Publicado: (2010)

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
por: Short, Nicholas J., et al.
Publicado: (2022)

Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG)
por: Kayıkçı, Ömür, et al.
Publicado: (2022)

Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party
por: Kim, Da Jung, et al.
Publicado: (2017)

Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers
por: Başcı, Semih, et al.
Publicado: (2021)

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
por: Lee, Sangmin, et al.
Publicado: (2022)

Management of myelodysplastic syndromes after failure of response to hypomethylating agents
por: Gil-Perez, Angela, et al.
Publicado: (2019)

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies
por: Feld, Jonathan, et al.
Publicado: (2021)

Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy
por: Singh, Ratnakar, et al.
Publicado: (2021)

Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells
por: Sharma, Anup, et al.
Publicado: (2017)

Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1fu4op1de0no76j193ka4r7obj